6 курс / Кардиология / СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ

Литература

405.Sabbah H.N. Apoptotic cell death in heart failure // Cardiovasc. Res. – 2000. – Vol. 45. – P. 704–712.

406.Sakashita N., Anda Y., Marlund S.L. et al. Familial amyloidotic polyneuropathy type I with extracellular superoxide dismutase mutation: a case report // Hum. Pathol. – 1994. – No. 29 –

P.1169–1172.

407.Samali A., Zhivotovsky B., Jones D. et al. Apoptosis: cell death defined by caspase activation // Cell Death Differ. – 1999. – Vol. 6. – P. 495–496.

408.San J., Fortuno A., Beloqui O. et al. NADPH oxidase CYBA poly; morphisms, oxidative stress and cardiovascular diseases // Clin. Sci. (Lond). – 2008. – Vol. 114, No. 3. – Р. 173–182.

409.Sarto P., Balducci E., Balconi G. et al. Effects of exercise training on endothelial progenitor cells in patients with chronic heart fail; ure // J. Card. Fail. – 2007. – Vol. 13 (9). – Р. 701–708.

410.Sato K., Laham R.J., Pearlman J.D. et al. Efficacy of intracoro; nary versus intravenous FGF;2 in a pig model of chronic myocar; dial ischemia // Ann. Thorac. Surg. – 2000. – Vol. 70 (6). – Р. 2113–2118.

411.Saunders K.B., D’Amore P.A. FGF and TGF;beta actions and in; teractions in biological systems // Crit. Rev. Eukar. Gene Experes.

– 1991. – Vol. 3. – Р. 165–172.

412.Schachinger V., Britten M.B., Dimmeler S., Zeiher A.M. NADH/ NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function // Eur. Heart

J.– 2001. – Vol. 22, No.1. – Р. 96–101.

413.Schnabel R., Lackner K.J., Tupprecht H.J. et al. Glutatione Per; oxidase;1 and homocysteine for cardiovascular risk prediction // J. Am. Coll. Cardiol. – 2005. – Vol. 45. – Р. 1631–7163.

414.Shah P.K. Role of inflammation and metalloproteinases in plaque disruption and thrombosis // Vasc. Med. – 1998. – Vol. 3. – Р. 199–206.

415.Sharov V.G., Sabbah H.N., Shimoyama H. et al. Evidence of car; diocyte apoptosis in myocardium of dogs with chronic heart fail;

389

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

ure // Am. J. Pathol. – 1996. – Vol. 148. – P. 141–149.

416.Shichiri M., Kato H., Marumo F. et al. Endothelin;1 as an auto; crine/paracrine apoptosis survival factor for endothelial cells // Hypertension. – 1997. – Vol. 30. – Р. 1198–1203.

417.Shimoda;Matsubayoshi S., Matsumine H., Kobayashi T. et al. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene // Bio; chem. Biophys. Res. Commun. – 1996. – Vol. 226. – P. 561–565.

418.Shou M., Thirumurti V., Rajanayagam M. Effect of basic fibro; blast growth factor on myocardial angiogenesis in dogs with mature collateral vessels // J. Am. College Cardiol. – 1997. – Vol. 29 (5). – Р. 1102–1106.

419.Shyu K.G., Lu M.J., Chang H. et al. Carvedilol modulates the ex; pression of hypoxia;inducible factor;1alpha and vascular endot; helial growth factor in a rat model of volume;overload heart fail; ure // J. Card. Fail. – 2005. – Vol. 11 (2). – Р. 152–159.

420.Sigurdsson A., Swedberg K. The role of neurohormonal activa; tion in chronic heart failure and postmyocardial infarction // Am. Heart J. – 1996. – Vol. 132 (1 Pt 2 Su). – Р. 229–234.

421.Silence J., Lupu F., Collen D., Lijnen H. R. Persistence of athero; sclerotic plaque but reduced aneurysm formation in mice with stromelysin;1 (MMP;3) gene inactivation // Arterioscler. Thromb. Vasc. Biol. – 2001. – Vol. 21. – P. 1440–1445.

422.Slater A.F.G., Stefan C., Nobel I. et al. Intracellular redox chang; es during apoptosis // Cell Death Differentiation. – 1996. – Vol. 3. – P. 57–62.

423.Smith J.G., Melander O., Sjogren M. et al. Genetic polymorphisms confer risk of atrial fibrillation in patients with heart failure: a pop; ulation;based study // Eur. J. Heart Fail. – 2013. –Vol. 15 (3). – P. 250–257.

424.Spinale F.G. Matrix metalloproteinases: Regulation and dysreg; ulation in the failing heart // Сirc. Res. – 2002. – Vol. 90. – Р. 520–530.

425.Spinarova L., Spinar J., Vasku A. et al. Big endothelin in chronic

390

Литература

heart failure: marker of disease severity or genetic determina; tion? // Int. J. Cardiol – 2004. – Vol. 93. – P. 63–68.

426.Srisawasdi P., Vanavanan S., Charoenpanichkit C. et al. The ef; fect of renal dysfunction on BNP, NT;proBNP, and their ratio // Am. J. Clin. Pathol. – 2010. – Vol. 133 (1). – Р. 14–23.

427.Stamatis A., John T.P., Michael G. et al. Growth hormone admin; istration reduces circulating proinflammatory cytokines and sol; uble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy // Am. Heart J. – 2002 – Vol. 144 (2). – Р. 359–364.

428.Stannard A.K., Khurana R., Evans I.M. et al. Vascular endothelial

growth factor synergistically enhances induction of E;selectin by TNF;α // Arterioscler. Thromb. Vasc. Biol. – 2007. – Vol. 27. – P. 494–502.

429.Stephanou A., Scarabelli T.M., Brar B.K. et al. Induction of apop; tosis and Fas receptor/Fas ligand expression by ischemia/rep; erfusion in cardiac myocytes requires serine 727 of the STAT;1 transcription factor but not tyrosine 701 // J. Biol. Chem. – 2001.

– Vol. 276. – P. 28340–28347.

430.Sullivan A., Syed N., Gasco M. Polymorphism in wild;type p53 modulates response to chemotherapy in vitro and in vivo // On; cogene. – 2004. – Vol. 23. – P. 3328–3337.

431.Sun Y., Zhang J., Lu L. et al. Aldosterone;induced inflammation in the rat heart role of oxidative stress // Am. J. Pathol. – 2002. – Vol. 161 (5). – Р. 1773–1781.

432.Suzuki Т., Coggan M., Shaw D.V., Board P.G. Electrophoretic and immunological analysis of human glutathione S;transferase isozymes // Annals of Human Genetics. – 1987. – Vol. 51. – Р. 95–106.

433.Swynghedauw B. Molecular mechanisms of myocardial remod; eling // Physiological Reviews. – 1999. – Vol. 79, No. 1. – P. 216– 248.

434.Sylven С. Angiogenic Gene Therapy // Drugs of Today. – 2002. – Vol. 38 (12). – Р. 819–827.

391

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

435.Symes J.F., Losordo D.W., Vale P.R. Gene therapy with VEGF for inoperable coronary artery disease // Ann. Thorac. Surg. – 1999.

–Vol. 68. – Р. 830–836.

436.Szaflik J.P., Wysocki T., Kowalski M. et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy // Graefes. Arch. Clin. Exp. Ophthalmol.

–2008. – Vol. 246 (1). – P. 39–43.

437.Takemura G., Kanoh M., Minatoguchi S., Fujiwara H. Cardiomy; ocyte apoptosis in the failing heart – a critical review from defini; tion and classification of cell death // Int. J. Cardiol. – 2013. – Vol. 167 (6). – P. 2373–2386.

438.Tan S., Sagara Y., Liu Y. et al. The regulation of reactive oxygen species production during programmed cell death // J. Cell. Biol.

–1998. – Vol. 141 (6). – P. 1423–1432.

439.Tanaka M., Suda Т., Haze K. et al. Fas ligand in human serum // Nature Med. – 1996. – Vol. 2. – P. 317–322.

440.Tang Y.L., Zhao Q., Zhang Y.C. et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium // Regul. Pept. – 2004. – Vol. 117. – P. 3–10.

441.Tanowitz H.B., Huang H., Jelicks L.A. et al. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease // Infect. Immun. – 2005. – Vol. 73. – P. 2496–2503.

442.Tendera M. Epidemiology, treatment, and guidelines for the treat; ment of heart failure in Europe // Eur. Heart J. – 2005. – Vol. 7 (Suppl. J). – P. 5–9.

443.Thrailkill K., Cockrell G., Simpson P. еt al. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens // Clin. Chem. Lab. Med. – 2006. – Vol. 44 (4). – P. 503–504.

444.Tiroch K., Koch W., Mehilli J. et al. P27 and P53 gene polymor; phisms and restenosis following coronary implantation of drug; eluting stents // Cardiology. – 2009. – Vol. 112 (4). – Р. 263–269.

445.Tischer E., Mitchell R., Hartman Т. et al. The human gene for vas;

392

Литература

cular endothelial growth factor // J. Biol. Chem. – 1991. – Vol. 266. – Р. 11947–11954.

446.Tiyyagura S.R., Pinney S.P. Left ventricular remodeling after my; ocardial infarction: past, present, and future // Mt. Sinai J. Med.

–2006. – Vol. 73 (6). – P. 840–851.

447.Toffoli G., Russo A., Innocenti F. Effect of methylenetetrahydro; folate reductase 677C’!T polymorphism on toxicity and homocys; teine plasma level after chronic methotrexate treatment of ovari; an cancer patients // Int. J. Cancer. – 2003. – Vol. 103 (3). – P. 294–199.

448.Toyozaki T., Hiroe M., Tanaka M. et al. Levels of soluble Fas ligand in myocarditis // Am. J. Cardiol. – 1998. – Vol. 82. – P. 246–248.

449.Tsuruda T., Boerrigter G., Huntley B.K. et al. Brain natriuretic pep; tide is produced by cardiac fibroblastsand induces matrix metal; loproteinases // Circ. Res. – 2002. – Vol. 91. – P. 1127–1131.

450.Tsutsumi Y., Losordo D.W. Double face of VEGF // Circulation. – 2005. – Vol. 112. – P. 1248–1250.

451.Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders // FASEB J. – 2001. – Vol. 15. – P. 312–332.

452.Unger T. Neurohormonal modulation in cardiovascular disease // Am. Heart J. – 2000. – Vol. 139. – P. S2–S8.

453.Uretsky B.F., Jessup M., Konstam M.A. et al. For the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo // Circulation. – 1990. – Vol. 82 (3). – Р. 774–780.

454.Valli N., Georges A., Corcuff J.B. et al. Assessment of brain natri; uretic peptide in patients with suspected heart failure: compari; son with radionuclide ventriculography data // Clin. Chim. Acta.

–2001. – Vol. 306. – Р. 19–26.

455.Van der Meer P., De Boer R.A., White H.L. et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prog; nosis in patients with chronic heart failure: a MERIT;HF substudy

393

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

// J. Card. Fail. – 2005. – Vol. 11 (4). – Р. 279–284.

456.Vanderheyden M., Bartunec J. Brain and other natriuretic pep; tides: molecular aspects // Eur. J. Heart Fail. – 2004. – Vol. 3. – Р. 261–267.

457.Vassalle C., Andreassi M.G., Prontera C. et al. Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure // Clin Chem. – 2007. – Vol. 53 (11). – Р. 1886–1890.

458.Vatter H., Zimmermann M., Tesanovic V. et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cere; bral vasospasm. Part I: inhibitory effect on endothelin(A) recep; tor;mediated contraction // J. Neurosurg. – 2005. – Vol. 102. – P. 1101–1107.

459.Venkataraman K., Khurana S., Tai T.C. Oxidative stress in aging; matters of the heart and mind // Int. J. Mol. Sci. – 2013. – Vol. 14

(9). – P. 17897–17925.

460.Vila V., Martinez;Sales V., Almenar L. et al. Inflammation, endot; helial dysfunction and angiogenesis markers in chronic heart fail; ure patients // Int. J. Cardiol. – 2008. – Vol. 130 (2). – Р. 276– 277.

461.Voetsch B., Jin R. C., Bierl C. et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx;3) gene: a novel risk factor for arterial ischemic stroke among young adults and chil; dren // Stroke. – 2006. – Vol. 38, No. 1. – Р. 41–49.

462.Waltenberger J. Impaired collateral vessel development in dia; betes; potential mechanisms and therapuetic implications // Cardiovasc Res. – 2001. – Vol. 49. – Р. 554–560.

463.Wang T.J., Larson M.G., Levy D. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death // N. Engl. J. Med. – 2004. – Vol. 350. – Р. 655–663.

464.Wang X.L., Adachi Т., Sim A.S. et al. Plasma extracellular super; oxide dismutase levels in an Australian population with coronary artery disease // Arteroiscler. Thromb. Vase. Biol. – 1998. –

394

Литература

Vol. 18 – P. 1915–1921.

465.Wang Z.B., Liu Y.Q., Cui Y.F. Pathways to caspase activation // Cell. Biol. Int. – 2005. – Vol. 29 (7). – Р. 489–496.

466.Washio T., Nomoto K., Watanabe I. et al. Relationship between plasma homocysteine levels and congestive heart failure in pa; tients with acute myocardial infarction. Homocysteine and con; gestive heart failure // Int. Heart J. – 2011. – Vol. 52. – Р. 224– 228.

467.Weber K.T. Cardioreparation in hypertensive heart disease // Hypertension. – 2001. – Vol. 38 (3 Pt 2). – P. 588–591.

468.Westenbrink B.D., Lipsic E., van der Meer P. et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization // Eur. Heart J. – 2007. – Vol. 28 (16). – Р. 2018–2027.

469.Williams R.S. Apoptosis and heart failure // N. Engl. J. Med. – 1999. – Vol. 341. – P. 759–760.

470.Woodard G.E., Rosado J.A. Natriuretic peptides in vascular phys; iology and pathology // Int. Rev. Cell Mol. Biol. – 2008. – Vol. 268. – Р. 59–93.

471.Wrigley B.J., Lip G.Y., Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure // Eur. J. Heart Fail. – 2011. – Vol. 13 (11). – P. 1161–1171.

472.Xia J.H., Xie A.N., Zhang K.L. et al. The vascular endothelial growth factor expression and vascular regeneration in infarcted myocardium by skeletal muscle satellite cells // Chin. Med. J. – 2006. – Vol. 119 (2). – Р. 117–121.

473.Xiao J., She Q., Wang Y. et al. Effect of allopurinol on cardiomyo; cyte apoptosis in rats after myocardial infarction // Eur. J. Heart Failure. – 2009. – Vol. 11, No. 1. – P. 20–27.

474.Xie J., Yi L., Xu Z.F. et al. VEGF C;634G polymorphism is associ; ated with protection from isolated ventricular septal defect: case; control and TDT studies // Eur. J. Hum. Genet. – 2007. – Vol. 15 (12). – 1246–1251.

395

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

475.Yamada Y., Izawa H., Ichihara S. et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes //

N.Eng. J. Med. – 2002. – Vol. 347 (24). – P. 1916–1923.

476.Yamammoto S., Sawada K., Shimomura H. et al. On the nature of cell death during remodeling of hypertrophied human myocardi; um // J. Mol. Cell Cardiol. – 2000. – Vol. 32. – Р. 161–175.

477.Yamamura T., Nakamura H., Yamamoto T. et al. Fas expression and apoptosis correlate with cardiac dysfunction in patients with dilated cardiomyopathy // Jpn. Circ. J. – 1999. – Vol. 63. –

P.149–154.

478.Yang B., Ye D., Wang Y. Caspase;3 as a therapeutic target for heart failure // Expert Opin. Ther. Targets. – 2013. – Vol. 17 (3). – 255–263.

479.Ye H., Li X., Wang L. et al. Genetic associations with coronary heart disease: meta;analyses of 12 candidate genetic variants // Gene. – 2013. – Vol. 531 (1). – P. 71–77.

480.Ye S. Influence of matrix metalloproteinase genotype on cardio; vascular disease susceptibility and outcome // Cardiovasc. Re; search. – 2006. – Vol. 69 (3). – Р. 636–645.

481.Ye S., Watts G.F., Mandalia S. et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis // Brit. Heart J. – 1995.

–Vol. 73 (3). – P. 209–215.

482.Yip H.K., Wu C.J., Chang H.W. et al. Prognostic value of circulat; ing levels of endothelin;1 in patients after acute myocardial inf; arction undergoing primary coronary angioplasty // Chest. – 2005. – Vol. 127. – P. 1491–1497.

483.Yonish;Rouach E., Resnitzky D., Lotem J. et al. Wild;type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin;6 // Nature. – 1991. – Vol. 352. – Р. 345–347.

484.Yoshiji H., Kuriyama S., Yoshii J. et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma // Hepatology. – 2002. – Vol. 35. – P. 834–842.

396

Литература

485.Yue T.L., Ma X.L., Wang X. et al. Possible involvement of stress; activates protein kinase signalling pathway and Fas receptor ex; pression in prevention of ischemia;induced cardiomyocute apo; ptosis by carvedilol // Circ Res. – 1998. – Vol. 82. – Р. 166–174.

486.Yue T.L., Ohlstein E.H., Ruffolo R.R. Jr. Apoptosis: a potential tar; get for discovering novel therapies for cardiovascular diseases // Curr. Opinion Chem. Biol. – 1999. – Vol. 3. – Р. 474–480.

487.Zachary I., Mathur A., Yla;Herttuala S. et al. Vascular protection: a novel nonangiogenic cardiovascular role for VEGF // Arterio; scler. Thromb. Vasc. Biol. – 2000. – Vol. 20. – P. 1512–1520.

488.Zeller T., Blankenberg S., Diemert P. Genomewide association studies in cardiovascular disease – an update 2011 // Clin. Chem.

– 2012. – Vol. 58 (1). – P. 92–103.

489.Zhang Z.W., Lin Z.P. Response to metoprolol succinate sustained; release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C;reactive protein in elderly hyper; tensive patients with chronic heart failure // Nan Fang Yi Ke Da Xue Xue Bao. – 2010. – Vol. 30 (9). – Р. 2171–2174.

490.Zheng H., Liu X., Li Y., Patel K.P. Gene transfer of neuronal nitric oxide synthase to the paraventricular nucleus improves enhanced NMDA NR1 receptor function in rats with chronic heart failure // FASEB J. – 2007. – Vol. 21. – P. 1267.

491.Zheng W., Seftor E.A., Meininger C.J. et al. Mechanisms of cor;

onary angiogenesis in response to stretch: role of VEGF and TGF;α // Amer. J. Phisiol. Heart Circ. Phisiol. – 2001. – Vol. 280.

– P. 909–917.

492.Zolk O., Bohm M. The role of the cardiac endothelin system in heart failure // Nephrol. Dial. Transplant. – 2000. – Vol. 15. – P. 758–760.

397

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

398